TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical announced a webinar on October 22, 2021, focusing on SARS-CoV-2 testing strategies for long-term care facilities. The company published an article in the Journal of Clinical Virology, emphasizing a combined approach of cPass neutralizing antibody tests and PCR testing to reduce COVID-19 transmission. Provista Dx, a subsidiary of Todos, offers high-throughput testing services. Todos Medical is also involved in developing diagnostic tests and therapeutic candidates for COVID-19. The forward-looking statements highlight associated risks and uncertainties with clinical programs and market competition.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a webinar featuring Dr. Jorge Leone and Sean Taylor to discuss the cPass™ SARS-COV-2 neutralizing antibody test. The session, titled 'A New Paradigm for Measuring Immunity in a Pre- and Post-Vaccination Era,' aims to educate the medical community on the significance of the test. cPass is currently the only emergency use authorized neutralizing antibody test, crucial for assessing immunity in high-risk populations. The webinar is scheduled for October 22, 2021, at 12 PM EDT and will be streamed live on YouTube.

Todos Medical (OTCQB: TOMDF) has announced positive clinical validation for its TolloTest™, a 3CL protease biomarker assay, demonstrating 100% sensitivity for identifying COVID-19 in fully vaccinated asymptomatic patients 1-3 days post-exposure. The assay shows a high correlation with PCR results, indicating its potential as a more effective diagnostic tool for assessing COVID-19 infectivity. The company plans to explore various assay formats to improve ease of use and aims for emergency use authorization (EUA) for its product.

Todos Medical, Ltd. (OTCQB: TOMDF) announced its participation in multiple industry conferences in October 2021. CEO Gerald Commissiong will moderate and present at events including Longwood Healthcare Leaders and BioFuture. Todos Medical specializes in medical diagnostics, focusing on cancer detection and COVID-19 testing. The company's proprietary technologies, such as TBIA and Videssa, aim to enhance early diagnosis capabilities. The firm also engages in developing blood tests for neurodegenerative disorders and distributing COVID-19 testing supplies.

Todos Medical (OTCQB: TOMDF) updated its clinical development program for the COVID-19 oral antiviral Tollovir®, currently in a Phase 2 trial in Israel. Following Merck's trial halting enrollment due to a significant reduction in COVID-related hospitalization and death rates, Todos plans to re-evaluate outpatient trial designs. Presently, 27 of 77 patients are enrolled, with the next safety analysis at 33 patients expected soon. The company has a strong safety profile for Tollovir, previously deemed safe for widespread use by regulatory agencies, including the US FDA.

Todos Medical (OTCQB: TOMDF) announced promising results from an observational study of 32 hospitalized COVID-19 patients treated with Tollovir®. The study found that 50% of treated patients achieved a significant reduction in the inflammatory biomarker C-Reactive Protein (CRP), compared to 10% in the control group. Importantly, no deaths occurred in the Tollovir group, while five deaths were recorded in the observational group. The mean hospitalization days were also lower for the Tollovir group (13.3 days) compared to the control (17.4 days). The results suggest Tollovir's potential in treating severe COVID-19 cases.

Todos Medical (OTCQB: TOMDF) has announced its participation in several industry conferences in October, aiming to highlight advancements in diagnostics. CEO Gerald Commissiong will speak at notable events including the Wall Street Journal Future of Health and the Longwood Healthcare Leaders Webconference. Todos Medical focuses on cancer detection and COVID-19 diagnostic solutions, with proprietary tests like Videssa® and ongoing clinical trials for Tollovir™ targeting COVID-19. The company aims to commercialize its innovative diagnostic technologies and expand its presence in the healthcare market.

Tollovid® and Tollovid Daily™ are now available on Amazon, enhancing Todos Medical's market presence. The 3CL protease inhibiting supplements are designed for immune function support. With Amazon's vast reach, the company expects increased sales, particularly during the holiday season when immune health is crucial. CEO Gerald Commission highlighted the importance of this move for brand visibility. Todos Medical, known for its diagnostic solutions and dietary supplements, is positioned to capitalize on the growing demand for health products, especially amid rising health risks.

Todos Medical reported a positive net income of $3.39 million or $0.01 per share for Q2 2021, with revenue soaring to $1.7 million from $32,000 a year prior. The acquisition of Provista Diagnostics enhances the company’s capabilities in breast cancer testing and COVID-19 diagnostics. A Phase 2 clinical trial for its antiviral, Tollovir, is underway, with expectations to expand into India. The company received FDA approval for a new Tollovid regimen, bolstering its market presence. It aims for improved financial health and potential uplisting to a national exchange.